MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

GlobeImmune Company Profile (NASDAQ:GBIM)

Consensus Ratings for GlobeImmune (NASDAQ:GBIM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for GlobeImmune (NASDAQ:GBIM)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for GlobeImmune (NASDAQ:GBIM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/12/2016        
5/12/2016Q1($0.27)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for GlobeImmune (NASDAQ:GBIM)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for GlobeImmune (NASDAQ:GBIM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for GlobeImmune (NASDAQ:GBIM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/18/2016Augustine LawlorDirectorSell11,000$1.55$17,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Daniel J MitchellDirectorSell21,600$1.66$35,856.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Daniel J MitchellDirectorSell130,269$2.26$294,407.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Augustine LawlorDirectorSell16,500$1.60$26,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2016Daniel J MitchellDirectorSell16,400$1.17$19,188.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Augustine LawlorDirectorSell15,010$1.05$15,760.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Daniel J MitchellDirectorSell11,920$1.05$12,516.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Augustine LawlorDirectorSell15,990$1.11$17,748.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Daniel J MitchellDirectorSell17,422$1.02$17,770.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Daniel J MitchellDirectorSell8,799$0.96$8,447.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016Augustine LawlorDirectorSell15,000$0.98$14,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Daniel J MitchellDirectorSell12,501$1.03$12,876.03View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2016Augustine LawlorDirectorSell15,000$1.33$19,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2016Daniel J MitchellDirectorSell22,858$1.42$32,458.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Augustine LawlorDirectorSell5,000$1.43$7,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2016Ventures Vii Lp HealthcareInsiderSell15,000$1.44$21,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2016Daniel J MitchellDirectorSell21,897$1.45$31,750.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Ventures Vii Lp HealthcareMajor ShareholderSell15,000$1.61$24,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Daniel J MitchellDirectorSell3,645$1.75$6,378.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2016Daniel J MitchellDirectorSell7,300$2.05$14,965.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2014Celgene International IncMajor ShareholderBuy200,000$10.00$2,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2014S. Edward TorresDirectorBuy85,000$10.00$850,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2014Timothy C Rodell JrCEOBuy5,000$10.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for GlobeImmune (NASDAQ:GBIM)
DateHeadline
06/22/16 08:49 AMGlobeImmune Inc (NASDAQ:GBIM): We Bought The Stock At $1.93 and Sold at $3.30, Amazing Quick profit
06/20/16 10:22 AMIs this Colorado biotech a takeover target?
06/20/16 10:22 AMGlobeImmune Inc (NASDAQ:GBIM): That’s Why Profit Taking Is Must, Reached Our Target on Friday, Now Down
06/20/16 10:22 AMGlobeImmune Inc (NASDAQ:GBIM): How Did Our members Trade The Stock? Massive Win In A Single Day
06/19/16 08:28 AMGlobeImmune Inc (NASDAQ:GBIM): It’s All About Chart For The Momentum Trade
06/18/16 08:39 AMGlobeImmune Inc (NASDAQ:GBIM): Just Reached Our Target of $3.30 In 24 Hours – Made 70%
06/17/16 04:02 PMThese Four Companies Are a Must for Your Watchlist, in June
06/17/16 04:02 PMGlobeImmune Inc (NASDAQ:GBIM) And EXACT Sciences Corporation (NASDAQ:EXAS) Are Big Winners Of This Week
06/16/16 04:09 PMU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.53%
06/16/16 12:42 PMWhy Korn/Ferry, AMD, Wells Fargo & Two Other Stocks Are in Spotlight Today -
03/11/16 10:47 AMMarkets Rally Belatedly To ECB Bazooka (GBIM) -
02/26/16 09:20 AMGlobeImmune’s CEO cuts own hours, salary to preserve capital - LOUISVILLE — GlobeImmune Inc.’s chief executive Timothy C ... In August, GlobeImmune. (Nasdaq: GBIM) reduced its workforce from 22 to six employees, according to documents filed with the SEC, in an effort to preserve cash after negative trial results ...
02/23/16 03:12 PMGLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
12/08/15 12:18 PMGLOBEIMMUNE INC Financials -
11/13/15 08:12 AMGLOBEIMMUNE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
11/13/15 05:30 AMGlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights - [Marketwired] - GlobeImmune, Inc. , a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen® platform, today announced its third ...
11/13/15 05:15 AMGLOBEIMMUNE INC Files SEC form 10-Q, Quarterly Report -
11/03/15 11:08 AMGlobeImmune, Inc. – Value Analysis (NASDAQ:GBIM) : November 3, 2015 -
09/30/15 10:04 AMGlobeImmune, Inc. Earnings Q2, 2015 -
08/14/15 05:30 AMGlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights - [Marketwired] - GlobeImmune, Inc. , a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen® platform, today announced its second ...
08/13/15 05:30 AMGlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options - [Marketwired] - GlobeImmune, Inc. , a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen® platform, announced today that it has ...
08/04/15 03:29 PMGLOBEIMMUNE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
07/17/15 03:31 PMGLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers -
07/13/15 03:12 PMGLOBEIMMUNE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
07/01/15 07:02 AMCan Hepatitis B Be A Blockbuster Bug? -
About GlobeImmune

GlobeImmune, Inc. (GlobeImmune) is a biopharmaceutical company. The Company is focused on developing therapeutic products for cancer and infectious diseases based on its Tarmogen platform. The Company has four Tarmogen product candidates in five ongoing clinical trials. The Company has two collaborations with biotechnology companies. Gilead Sciences, Inc. (Gilead), exclusively licenses product candidates to treat chronic hepatitis B virus (HBV) infection. Celgene Corporation (Celgene) entered into collaboration with the Company for certain oncology product candidates. Celgene exercises its option for across the world, exclusive license to the GI-6300 program, which is a Tarmogens program targeting the brachyury protein. The Company has no products approved for commercial sale, and as of September 30, 2014, it has not generated any product revenue.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GBIM
  • CUSIP:
Key Metrics:
  • Previous Close: $2.16
  • 50 Day Moving Average: $1.54
  • 200 Day Moving Average: $2.25
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $12.42M
  • Current Quarter EPS Consensus Estimate: $N/A EPS
Additional Links:
GlobeImmune (NASDAQ:GBIM) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha